Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

OMB control number.

OIVIB CO	Substitute for form 1	449/PTO		Complete if Known	OPAS	
	INFORMATION DISC	CLOSURE	Application Number	09/622,646		\mathcal{I}
	STATEMENT BY AF		Filing Date	2/25/1999	- MID A	51
	Data Calandata da Man		First Named Inventor	Yasuko OZAKI	3 MAR 2 8 2011	<u> </u>
	Date Submitted: Mar	cn 28, 2011	Art Unit	1641	图	<u>u/</u>
•	(use as many sheets a	s necessary)	Examiner Name	Christine E. FOS		<u></u>
Sheet	1 of	1	Attorney Docket Number	053466-0286	MADEMARKO	

			U.S. PATENT DO	CUMENTS	
Examin er Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite item (hook magazine journal serial symposi		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	F1	Gerd ZETTLMEISSL, et al., "Expression and Characterization of Human CD4: Immunoglobulin Fusion Proteins", DNA AND CELL BIOLOGY, 1990, Volume 9, Number 5, pages 347-353	
	F2	Shuji OZAKI, et al., "Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24", BLOOD, October 15, 1997, Volume 90, Number 8, pages 3179-3186	
	F3	Shuji OZAKI, et al., "Preferential Expression of Human \(\lambda\)-Light-Chain Variable-Region Subgroups in Multiple Myelome, AL Amyloidosis, and Waldenström's Macroglobulinemia", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, May 1994, Volume 71, Number 2, pages 183-189	
. ,,	F4	Tetsuya GOTO, et al., "A Novel Membrane Antigen Selectively Expressed on Terminally Differentiated Human B Cells", BLOOD, September 15, 1994, Volume 84, Number 6, pages 1922-1930	

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.